Ekso Bionics Holdings, Inc. (EKSO) Downgraded by Zacks Investment Research to Sell
Zacks Investment Research downgraded shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) from a hold rating to a sell rating in a research report released on Monday morning.
According to Zacks, “Ekso Bionics Holdings, Inc. is engaged in designing, developing and selling wearable robots or exoskeletons for the medical, military, industrial and consumer markets. The company’s operating segment consists of Engineering Services and Medical segments. It operates primarily in North America, Western Europe, the Middle East and South Africa. Ekso Bionics Holdings, Inc. is headquartered in Richmond, California. “
Ekso Bionics Holdings (NASDAQ:EKSO) traded up $0.49 on Monday, hitting $2.02. The stock had a trading volume of 18,841,500 shares, compared to its average volume of 612,670. The company has a debt-to-equity ratio of 0.18, a current ratio of 6.09 and a quick ratio of 5.73. Ekso Bionics Holdings has a 1-year low of $0.99 and a 1-year high of $4.90.
Ekso Bionics Holdings (NASDAQ:EKSO) last released its quarterly earnings data on Wednesday, November 8th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.05). The company had revenue of $1.60 million for the quarter, compared to the consensus estimate of $2.40 million. Ekso Bionics Holdings had a negative return on equity of 323.00% and a negative net margin of 343.53%. equities research analysts forecast that Ekso Bionics Holdings will post -0.81 earnings per share for the current fiscal year.
In other news, insider Russ Angold sold 28,254 shares of the firm’s stock in a transaction on Wednesday, August 16th. The stock was sold at an average price of $1.53, for a total value of $43,228.62. Following the completion of the sale, the insider now owns 250,678 shares of the company’s stock, valued at $383,537.34. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In the last ninety days, insiders bought 41,264 shares of company stock valued at $48,255. 7.10% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. National Planning Corp boosted its position in Ekso Bionics Holdings by 122.2% during the third quarter. National Planning Corp now owns 520,942 shares of the company’s stock valued at $620,000 after purchasing an additional 286,492 shares during the last quarter. Carl Domino Inc boosted its position in Ekso Bionics Holdings by 125.2% during the third quarter. Carl Domino Inc now owns 184,788 shares of the company’s stock valued at $224,000 after purchasing an additional 102,734 shares during the last quarter. Intellectus Partners LLC boosted its position in Ekso Bionics Holdings by 5.3% during the second quarter. Intellectus Partners LLC now owns 105,294 shares of the company’s stock valued at $244,000 after purchasing an additional 5,294 shares during the last quarter. Finally, Vanguard Group Inc. boosted its position in Ekso Bionics Holdings by 32.9% during the second quarter. Vanguard Group Inc. now owns 711,082 shares of the company’s stock valued at $1,650,000 after purchasing an additional 176,197 shares during the last quarter. 2.85% of the stock is owned by hedge funds and other institutional investors.
Ekso Bionics Holdings Company Profile
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.
Receive News & Ratings for Ekso Bionics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.